Energy These Stocks Are Moving the Most Today: Exxon, Lockheed, Northrop, Delta, Mirati, Alnylam, SolarEdge, and More Oct. 9, 2023 at 4:14 p.m. ET by Barron's Biotech and Pharma Alnylam Stock Is Dropping on Surprising FDA Rejection Oct. 9, 2023 at 10:34 a.m. ET by Barron'...
Goldman Sachs issues surprising gold price target for 2025 The investment firm's analysts share their views about the precious metal. TSLA Investing News, Analysis, and Tips Feb 21, 2025 10:13 AM EST UnitedHealth stock plunges on report of DoJ Medicare Advantage probe UnitedHealth, still reelin...
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and...
We note that Givosiran is being evaluated for the treatment of acute hepatic porphyrias, including acute intermittent porphyria (AIP). A look at Alnylam's year-to-date share price movement shows that the stock has outperformed the Zacks classifiedMedical-Biomed/Geneticsindustry. Share price has...
ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can seethe complete list of today's Zacks #1 Rank (Strong Buy) stocks here ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.
Alnylam Pharmaceuticals MORE ON THIS TOPIC Mergers & acquisitions Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger March 5, 2025 · 2 min read · Tristan Manalac Podcasts Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter
Current Price $85.68 NASDAQ: EXEL Exelixis Market Cap $10B Current Price $37.02 NYSE: BMY Bristol Myers Squibb Market Cap $120B Current Price $59.99 Premium Investing Services Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's prem...
Share price of Alnylam declined 38.3% year to date compared with theindustry's decline of 17.7%. We note that, Anlylam is focused on the development of novel therapeutics based on RNAi. In August 2018, the FDA approved Alnylam's Onpattro (patisiran) lipid complex injection, a first-of-...